TL;DR
The research rationale for pairing GHRH analogs with selective ghrelin receptor agonists, combination protocols in preclinical somatotropic axis studies.
Research use only. This guide summarizes published research methodology for educational purposes. All Aureum Peptides products are sold strictly for in-vitro laboratory research.
Dual-Pathway Activation Rationale
GHRH receptors (pituitary) and GHS-R1a (ghrelin receptor) activate complementary pathways for GH release. Combining CJC-1295 (GHRH analog) with Ipamorelin (selective GHS) produces supra-additive GH release in published rodent and primate studies — a key research advantage over single-pathway activation.
Typical Research Concentrations
Published preclinical protocols commonly use CJC-1295 at 1–10 µg/kg and Ipamorelin at 50–300 µg/kg in rodent models. Specific concentrations vary widely by study design and endpoint measurement requirements.
GH Pulsatile Release Measurement
Serial blood sampling at 15–30 minute intervals for 4–6 hours post-administration, with radioimmunoassay or ELISA quantification of GH. Area under curve (AUC) and peak amplitude are standard endpoints.
Downstream IGF-1 Measurement
IGF-1 elevation follows GH peaks with 6–24 hour delay. Daily or every-48h IGF-1 measurement over 7–14 days captures downstream hepatic response.
Research Ordering from Aureum
Aureum Peptides offers both CJC-1295 (No DAC) and Ipamorelin in research-grade form, plus a pre-blended CJC-1295 + Ipamorelin Combo 10mg for streamlined combination research protocols.
Research-Grade Material from Aureum
Aureum Peptides provides research-grade peptides with ≥99% HPLC-verified purity and batch-specific Certificate of Analysis. Same-day dispatch on qualified orders placed before 2:00 PM EST.
Related guides:
Disclaimer: Educational content for qualified researchers. Not research information. No therapeutic claims. Peptides not approved by FDA for human use. For in-vitro laboratory research purposes only.
Last reviewed: 2026-04-21
